Skip to main content
Journal cover image

Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?

Publication ,  Journal Article
Phillips, JJ; Hall, MC; Lee, WR; Clark, PE
Published in: Urol Oncol
2007

PURPOSE: To assess whether a delay in initiating definitive therapy for clinically localized prostate cancer affects outcome. METHODS: We retrospectively reviewed 393 men with localized prostate cancer treated with radiation therapy or surgery without systemic therapy between 1991 and 2004. Data included: time from diagnosis to treatment initiation (more or less than 3 months); biopsy Gleason score grouped by low (2-6), intermediate (7), or high risk (8-10); clinical stage grouped by low (T1/T2a) or high risk (T2b or higher); pretreatment prostate-specific antigen (PSA) grouped by low (<10 ng/ml), intermediate (10-20), or high risk (>20); and biochemical recurrence-free survival. RESULTS: Median patient age was 63.1 years (range 39.7-79.5). Median pretreatment PSA was 6.5 ng/ml (range 0.4-411). Median time from diagnosis to treatment was 57 days (range 8-2927). A total of 310 patients (79%) were treated within 3 months. Median follow-up was 2.3 years (range 0.1-14.0). On univariate analysis using Kaplan-Meier survival curves and the log-rank test, only pretreatment PSA was associated with worse biochemical recurrence-free survival (P = 0.008). Biochemical recurrence-free survival was not associated with time from diagnosis to treatment (P = 0.28), clinical stage (P = 0.50), or biopsy Gleason score (P = 0.19). The results were the same when analyzed in a multivariable analysis using the Cox proportional hazards model. CONCLUSION: A delay in treatment of > or =3 months does not appear to affect adversely biochemical recurrence-free survival in patients who undergo definitive therapy for clinically localized prostate cancer in those with low risk features.

Duke Scholars

Published In

Urol Oncol

DOI

ISSN

1078-1439

Publication Date

2007

Volume

25

Issue

3

Start / End Page

196 / 200

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Time Factors
  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Humans
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Phillips, J. J., Hall, M. C., Lee, W. R., & Clark, P. E. (2007). Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Urol Oncol, 25(3), 196–200. https://doi.org/10.1016/j.urolonc.2006.06.004
Phillips, Joseph J., M Craig Hall, W Robert Lee, and Peter E. Clark. “Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?Urol Oncol 25, no. 3 (2007): 196–200. https://doi.org/10.1016/j.urolonc.2006.06.004.
Phillips, Joseph J., et al. “Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?Urol Oncol, vol. 25, no. 3, 2007, pp. 196–200. Pubmed, doi:10.1016/j.urolonc.2006.06.004.
Journal cover image

Published In

Urol Oncol

DOI

ISSN

1078-1439

Publication Date

2007

Volume

25

Issue

3

Start / End Page

196 / 200

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Time Factors
  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Humans
  • Disease-Free Survival